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Myricetin Inhibits Islet Amyloid Polypeptide (IAPP) Aggregation and  
Rescues Living Mammalian Cells from IAPP Toxicity 
Casey Zelusa, Ayano Foxa, Anastasia Calcianoa, Bianca S. Faridianb, Luiza A. Nogajb and David  
A. Moffeta* 
aDepartment of Chemistry and Biochemistry, Loyola Marymount University, 1 LMU Drive Los Angeles, CA 90045, USA 
bDepartment of Biology, Mount Saint Mary’s College 12001 Chalon Rd, Los Angeles, CA 90049, USA 
Abstract: The aggregation of the amyloidogenic polypeptide IAPP (Islet Amyloid Polypeptide, amylin) is believed to 
play a direct role in the death of pancreatic β-islet cells in type II diabetes. Preventing the initial aggregation event of 
IAPP is one strategy for slowing, and possibly preventing, the progression of this disease. Here, we investigate 
myricetin’s potential as an inhibitor of IAPP aggregation. We show that myricetin prevented thioflavin T binding in a 
concentration dependent manner. Atomic force microscopy revealed that myricetin prevented fiber formation under rigor-
ous conditions conducive to forming IAPP aggregates. Using an IAPP-EGFP (Enhanced Green Fluorescent Protein) pro-
tein construct, we find that high concentrations of myricetin slowed the in vivo aggregation of IAPP-EGFP. Myricetin was 
also found to rescue living mammalian cells from the toxic effects of IAPP. These results indicate that myricetin is a 
strong inhibitor of IAPP amyloid aggregation and a potential lead molecule for the development of an amyloid inhibiting 
therapeutic. 
Keywords: Type 2 diebetes, amyloid, amylin. 
 The aggregation of misfolded proteins has been directly 
linked to diseases such as type II diabetes, Alzheimer’s dis-
ease and Parkinson’s disease. It is believed that in each case, 
a protein misfolds and self-assembles into toxic oligomers 
and fibers, ultimately forming insoluble amyloid. While the-
se amyloidogenic proteins differ from each other in many 
ways, such as amino acid composition, protein length and 
organismal localization, those proteins appear to fold into β-
sheet structures that ultimately form toxic species. Even un-
natural proteins, designed to fold into β-sheet structures, ap-
pear to progress through similar pathways to form toxic 
amyloid species [1]. The misfolded amyloid protein found in 
the pancreas of individuals afflicted with type II diabetes is 
the 37-amino acid polypeptide IAPP (islet amyloid polypep-
tide, amylin). While the exact role of IAPP in type II diabe-
tes is unclear, insoluble IAPP is found in the extracellular 
deposits of amyloid in approximately 95% of patients af-
flicted with type II diabetes [2-4]. IAPP has also been shown 
to be a toxic agent in vitro when added to human islet β-cells 
[5]. 
 One therapeutic strategy for preventing or slowing the 
progression of amyloid diseases such as type II diabetes, is 
to inhibit the aggregation of the amyloidogenic proteins. It is 
believed that preventing the initial aggregation event could 
prevent the formation of toxic oligomers and fibers. Several 
polyphenol compounds have been shown to act as inhibitors 
of peptide aggregation for the amyloidogenic proteins Aβ  
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and tau (involved in Alzheimer’s disease) and α-synuclein 
(in Parkinson’s disease) [6-8]. Recently, several polyphenols 
have been shown to inhibit IAPP aggregation [9, 10]. Here 
we describe the ability of myricetin (Fig. 1) to inhibit the 
aggregation of IAPP in a concentration dependent manner. 
More importantly, we describe the ability of myricetin to 
rescue mammalian cells from the toxic effects of IAPP.  
 To test myricetin’s ability to inhibit IAPP aggregation, 
ThT-binding experiments were performed. When dissolved 
in an aqueous solution, ThT has negligible fluorescence 
emission when irradiated with 450 nm light. However, ThT 
fluorescence increases drastically upon binding to amyloid 
fibrils [11]. Synthetic IAPP (GenScript Corp.) was first dis-
aggregated in HFIP (Sigma) in a sonicating water bath. HFIP 
was removed over a steady stream of dry nitrogen gas. The 
resulting peptide sample was dissolved in 20 mM tris buffer 
pH 7.40 to yield an IAPP in-solution concentration of 106 
μM. Myricetin (Sigma) was dissolved in ethyl acetate and 
added to various in-solution concentrations (all samples con-
tained equivalent ethyl acetate concentrations). Aggregation 
 
Fig. (1). Chemical structure of myricetin. 
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was promoted by incubating samples at 37°C with shaking 
(200 rpm). An aliquot of each sample was removed at indi-
cated time points and mixed with 12.0 μM thioflavin T in 20 
mM Tris buffer pH 7.40. The thioflavin T mixture was incu-
bated at room temperature in the dark for 5 minutes before 
recording the thioflavin T fluorescence emission spectrum 
(Ex450nm) using a Hitatchi F-7000 fluorescence spectropho-
tometer.  
 
Fig. (2). ThT binding of IAPP in the presence of various concentra-
tions of myricetin. IAPP was 106 μM for all samples. The 1:10 
sample contained 10 μM myricetin, the 1:1 sample contained 100 
μM myricetin and the 10:1 sample contained 1 mM myricetin. Er-
ror bars represent the standard deviation of four separate trials. 
 IAPP is one of the most amyloidogenic peptides known. 
Under these aggregation-promoting conditions, IAPP began 
to bind ThT in less than 15 minutes of incubation (Fig. 2). In 
the presence of myricetin, ThT binding was reduced in a 
concentration-dependent manner. At the highest concentra-
tion of myricetin tested, where myricetin was at a 10-fold 
molar excess over IAPP, the ThT-binding of IAPP was ap-
proximately the same as ThT in solution in the absence of 
IAPP. The decrease in ThT fluorescence after reaching its 
maximum is commonly witnessed in these assays and is con-
sistent with previously reported amyloid aggregation reac-
tions [12, 13]. 
 AFM experiments showed that IAPP incubated under the 
aggregation-promoting conditions described above produced a variety of different insoluble aggregates (Fig. 3). Under 
these conditions, IAPP alone formed insoluble fibrils of var-
Fig. (3). Atomic force microscopy images of 106 μM IAPP (A) alone (B) with a 1:1 ratio of myricetin and (C) with a 10:1 molar excess of 
myricetin. Samples were incubated at 37oC for 45 minutes with vigorous shaking. 
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ious lengths, as well as yielded a preponderance of amor-
phous aggregates. When IAPP was incubated with a 10-fold 
molar excess of myricetin, virtually no insoluble aggregates 
were detected (Fig. 3). Under no conditions tested were we 
able to detect IAPP fibers when IAPP was incubated with a 
10x molar excess of myricetin. 
 The use of fluorescent protein fusions to amyloidogenic 
proteins has been shown to be an effective method for dis-
tinguishing relative levels of amyloidogenicity [14-20]. We 
constructed an IAPP-EGFP fusion protein for expression in 
E. coli [21]. Aggregation of the IAPP precludes folding, and 
hence fluorescence, of the EGFP fusion protein. Substances 
that prevent or slow IAPP aggregation allow the EGFP pro-
tein to fold and fluoresce. E. coli cells were induced with 1 
mM IPTG to express the IAPP-EGFP protein construct. 
Cells were incubated at 37oC with shaking in the absence 
and presence of myricetin (Fig. 4). Fluorescence intensity of 
the EGFP was highest when cells were incubated with 1 mM 
myricetin. Cells incubated without myricetin, or low concen-
trations of myricetin, showed less EGFP fluorescence.  
 To test the potential of myricetin to protect living cells 
from IAPP, PC12 cells were incubated with 10 μM of syn-
thetic IAPP (Fig. 5). The PC12 cells were cultured in 5% 
CO2 at 37º C in F-12K media (ATCC) supplemented with 
10% FBS (ATCC). The cells were plated in 96-well plates. 
After a twenty-four hour incubation, the F12-K media was 
substituted for DMEM/F12 (1:1) without phenol red and 
supplemented with 10% FBS (100 μL total volume/well). 
IAPP at 10 μM and/or myricetin at 10 M or 50 μM was 
added to the appropriate wells and incubated for 22 hours at 
37Ί C. MTT, dissolved at 0.3 mg/mL in DMEM without 
phenol red, was added to each well (10 μL/well) and incu-
bated for 2 hours at 37º C. The purple formazan crystals 
were dissolved using a solubilization buffer (50% dimethyl-
formamide and 20% SDS in water). The absorbance of each 
well was measured at 575 nm with a BioRad 550 microplate 
reader. Myricetin is only partially soluble in water, requiring 
DMSO for full solubilization. 
 
Fig. (4). Relative fluorescence intensity of E. coli expressing IAPP-
EGFP either alone or in the presence of myricetin. All samples 
show the fluorescence of E. coli expressing IAPP-EGFP. The fluo-
rescence increases when the E. coli are incubated with a high con-
centration of myricetin. Error bars represent the standard deviation 
of three separate trials.  
 The MTT assay, which quantitates the oxidative capacity 
of PC12 cells after treatment with IAPP alone, IAPP and 
myricetin, and myricetin alone, indicated that myricetin res-
cued the living cells from the toxic effects of IAPP. IAPP at 
 
Fig. (5). The effect of myricetin on the toxicity of IAPP in PC12 cells. Each well contained an equal density of PC12 cells. The MTT viabil-
ity assay was performed in triplicate. Each set of samples was calculated as a percentage of the control (cells alone). Error bars represent the 
standard deviation of the three separate assays. 
 
0
500
1000
1500
2000
IAPP‐EGFP
Alone
100 µM
Myricetin
1 mM
Myricetin
Fl
u
o
re
sc
e
n
ce
 (
Em
5
1
6
 n
m
) 
 
0
20
40
60
80
100
120
P
er
ce
n
t 
V
ia
b
ili
ty
 
Rescues Living Mammalian Cells from IAPP Toxicity The Open Biochemistry Journal, 2012, Volume 6    69 
10μM was toxic to the cells and reduced the MTT signal to 
71% compared to cells untreated with IAPP. At a 1 to 1 ratio 
of myricetin to IAPP, the cells were rescued back to 90% 
compared to untreated cells. At a ratio of 5:1 myricetin to 
IAPP, the cells were rescued to an MTT signal >96% com-
pared to untreated cells. Myricetin alone was found to have 
some effect on the PC12 cells. We found that a 5 fold excess 
of Myricetin alone (in the absence of IAPP) showed a 20% 
decrease in cellular viability. However, the combination of 
myricetin+DMSO was found to rescue the PC12 cells from 
IAPP, suggesting the interaction between myricetin and 
IAPP precludes toxicity of either myricetin or IAPP. 
 IAPP is a highly amyloidogenic protein directly linked to 
pancreatic β-cell death in type 2 diabetes. Our results show 
myricetin to be a strong inhibitor of IAPP amyloidogenic 
fiber formation. Insoluble IAPP aggregation was undetect-
able with either ThT binding or AFM when myricetin was 
incubated at a 10-fold molar excess with IAPP. This inhibi-
tion of IAPP aggregation was found to be dependent on the 
concentration of myricetin used. Myricetin was also found to 
inhibit IAPP aggregation in vivo, allowing the IAPP-EGFP 
fusion protein to fluoresce. Finally, myricetin was found to 
rescue living mammalian cells from the effects of toxic 
IAPP. These results indicate that myricetin is a potent inhibi-
tor of IAPP amyloid formation and a potential therapeutic 
lead for the treatment of amyloid diseases such as type 2 
diabetes. 
ABBREVIATIONS 
IAPP = Islet Amyloid Polypeptide 
ThT = thioflavin T 
HFIP = hexafluoroisopropanol 
AFM = atomic force microscope 
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IPTG = Isopropyl β-D-1-thiogalactopyranoside. 
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